Longoria named 4basebio commercial chief to turbocharge growth

The company develops and commercialises the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions and has just appointed Gabe Longoria as Chief Commercial Officer.

The appointment follows completion of a£40 million investment last November which marked a key milestone in the company’s journey to deliver scalable, high-quality synthetic DNA solutions to the global market –addressing critical needs in the gene therapy and mRNA vaccine sectors.

Longoria’s expertise in scaling commercial operations will play a crucial role in ensuring the company’s synthetic DNA products reach their full market potential and that 4basebio is well-positioned to deliver on its growth and commercialisation goals in 2025 and beyond.

He joins 4basebio following a successful tenure as Chief Commercial Officer at Astrea Bioseparations. During his leadership, Longoria supported the company in achieving exceptional financial growth, doubling revenues over a three-year period and expanding its market share globally.

He has over two decades of commercial leadership in the life sciences sector and expertise in driving revenue growth, market expansion, and strategic partnerships for companies.

Longoria said: “I am incredibly excited to join 4basebio at such a transformative stage in its journey. The company’s groundbreaking synthetic DNA technology has the potential to revolutionise the gene therapy and vaccine industries and I am eager to help bring these innovative products to a global audience.”

CEO Heikki Lanckriet added: “Gabe’s proven track record of driving commercial success, coupled with his deep understanding of the life sciences industry, makes him the perfect fit to lead our commercial strategy.

“As we focus on capitalising on our recent £40m investment, Gabe’s leadership will be invaluable in accelerating our efforts to bring our synthetic DNA products to market and deliver value to our customers and stakeholders.”